Atrium Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNA research report →
Range $25 – $25
Price Chart
About the company
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy.
- CEO
- Kathleen Gallagher
- IPO
- 2026
- Employees
- 511
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on RNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $136.33M
- P/E
- -2.07
- PEG
- 0.03
- P/S
- 5.80
- P/B
- 0.64
- EV/EBITDA
- -0.69
- Div Yield
- 0.00%
- Gross Margin
- 97.90%
- Op Margin
- -410.23%
- Net Margin
- -396.52%
- ROE
- -42.90%
- ROIC
- -38.39%
Latest fiscal year · YoY change
- Revenue
- $18.62M+0.0%
- Gross Profit
- $18.62M+0.0%
- Op Income
- $-76,814,000
- Net Income
- $-76,684,000+0.0%
- EPS
- $-4.48+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $16.77
- 52W Low
- $7.63
- 50D MA
- $11.33
- 200D MA
- $12.58
- Beta
- 0.37
- RSI (14)
- 26
- Avg Volume
- 252.33K
No earnings-call transcripts are available for RNA yet.
- Free Float
- 91.9%
- Shares Outstanding
- 17.11M
- Float Shares
- 15.72M
of shares held by institutions
168 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 13.65M | ▲ 429.49K |
| Ubs Oconnor LLC | 3.72M | ▲ 3.72M |
| Sessa Capital Im, L.P. | 1.50M | ▲ 948.61K |
| Price T Rowe Associates Inc | 1.47M | ▼ 80.23K |
| Blackrock, Inc. | 1.45M | ▲ 242.19K |
| Kryger Capital Ltd | 1.05M | ▲ 1.05M |
| Vanguard Capital Management LLC | 730.83K | ▲ 103.96K |
| Crcm LP | 641.54K | ▲ 641.54K |
| Tig Advisors, LLC | 561.53K | ▼ 46.02K |
| Geode Capital Management, LLC | 386.93K | ▲ 67.10K |
| Two Sigma Investments, LP | 345.48K | ▲ 166.92K |
| Goldman Sachs Group Inc | 310.34K | ▼ 39.61K |
Held by 142 ETFs
Biggest fund positions in RNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Younis Husam | other | 11,216 |
| Sep 18, 26 | Hughes Steven George | other | 21,459 |
| Sep 18, 26 | Flanagan W. Michael | other | 22,812 |
| Sep 18, 26 | Boyce Sarah | other | 126,418 |
| Sep 18, 26 | Kenney Stephanie | other | 2,375 |
| Sep 18, 26 | Gallagher Kathleen P. | other | 11,632 |
| Sep 18, 26 | Winslow Brendan R. | other | 6,742 |
| Sep 18, 26 | Hoyos Rocio Martin | other | 8,320 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RNA coverage
Recent articles, reports, and earnings notes.
No research on RNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNA report →Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Sep 21
Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?
defenseworld.net · Sep 10
Atrium Therapeutics to Participate in Upcoming Investor Conferences
prnewswire.com · Sep 2
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Aug 20
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
prnewswire.com · Aug 13
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
prnewswire.com · Aug 13
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
247wallst.com · Aug 6
Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average – Here’s Why
defenseworld.net · Jul 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.